





Effect of finerenone on the KCCQ in patients with HFmrEF/HFpEF: A prespecified analysis of FINEARTS-HF


Pardeep S Jhund

BHF Glasgow Cardiovascular Research Centre, University of Glasgow
& Queen Elizabeth University Hospital, Glasgow

FINEARTS-HF KCCQ: Results





FINEARTS-HF KCCQ: Results



	Experimental treatment	KCCQ Score	Month of assessment	Difference (95% CI)
PARAGON-HF	Sacubitril/valsartan	CSS	8	1.03 (0.00, 2.06)
EMPEROR-Preserved	Empagliflozin	CSS	12	1.32 (0.45, 2.19)
DELIVER	Dapagliflozin	TSS	8	2.4 (1.4, 3.4)


FINEARTS-HF KCCQ: Results




Consistent effect on KCCQ-TSS by subgroups

FINEARTS-HF KCCQ: Results

OR	0.92	1.04	1.08	1.15
95% CI	(0.81-1.03)	(0.94-1.16)	(0.97-1.20)	(1.03-1.28)
p=	0.14	0.45	0.16	0.01



FINEARTS-HF KCCQ: Results



Conclusion: The efficacy of finerenone was consistent across the range of KCCQ scores at baseline
Finerenone improved health related quality of life as measured by the KCCQ

Journal Pre-proof

Effect of finerenone on the KCCQ in patients with HFmrEF/HFpEF: A prespecified analysis of FINEARTS-HF

Mingming Yang, MD, PhD, Alasdair D. Henderson, PhD, Atefeh Talebi, PhD, John J. Atherton, MBBS, PhD, Chern-En Chiang, MD, PhD, Vijay Chopra, MB BS, MD, Josep Comin-Colet, MD, PhD, Mikhail N. Kosiborod, MD, Jose F. Kerr Saraiva, MD, PhD, Brian L. Claggett, PhD, Akshay S. Desai, MD MPH, Peter Kolkhof, PhD, Prabhakar Viswanathan, MBBS PhD, Andrea Lage, MD, Carolyn SP. Lam, MD PhD, Michele Senni, MD, Sanjiv J. Shah, MD, Katja Rohwedder, MD, Adriaan A. Voors, MD, PhD, Faiez Zannad, MD, PhD, Bertram Pitt, MD, Muthiah Vaduganathan, MD, MPH, Pardeep S. Jhund, MBChB MSc PhD, Scott D. Solomon, MD, John J.V. McMurray, MD

PII: S0735-1097(24)08532-2

DOI: <https://doi.org/10.1016/j.jacc.2024.09.023>

Reference: JAC 31269

To appear in: *Journal of the American College of Cardiology*

Received Date: 26 August 2024

Revised Date: 20 September 2024

Accepted Date: 20 September 2024

Please cite this article as: Yang M, Henderson AD, Talebi A, Atherton JJ, Chiang C-E, Chopra V, Comin-Colet J, Kosiborod MN, Kerr Saraiva JF, Claggett BL, Desai AS, Kolkhof P, Viswanathan P, Lage A, Lam CS, Senni M, Shah SJ, Rohwedder K, Voors AA, Zannad F, Pitt B, Vaduganathan M, Jhund PS, Solomon SD, McMurray JJV. Effect of finerenone on the KCCQ in patients with HFmrEF/HFpEF: A prespecified analysis of FINEARTS-HF, *Journal of the American College of Cardiology* (2024), doi: <https://doi.org/10.1016/j.jacc.2024.09.023>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that,



Simultaneously published in *JACC*

